Forte Biosciences, Inc. (FBRX)
NASDAQ: FBRX · Real-Time Price · USD
21.55
-0.45 (-2.07%)
At close: May 22, 2026, 4:00 PM EDT
21.59
+0.04 (0.21%)
After-hours: May 22, 2026, 4:10 PM EDT
Forte Biosciences Earnings Call Transcripts
Fiscal Year 2025
-
FB102 demonstrated statistically significant protection against gluten-induced gut inflammation and symptoms in a phase 1B celiac disease trial, with a favorable safety profile. A phase 2 trial is planned, aiming for broader efficacy and longer gluten challenge, with top-line data expected in 2026.